- ROUNDTABLE: Pharmacy’s future in sync with technology
- Study from NCPA sheds new light on med synchronization programs
- Senate passes Drug Quality and Security Act
- NCPA: Community pharmacy has historically helped patients as they transition to new health plans
- EXPERT BLOG: Provider status for pharmacists — one way or another
ORLANDO, Fla. — The independent community pharmacist members of the National Community Pharmacists Association on Wednesday approved resolutions addressing a range of pharmacy issues and elected a slate of leaders for the upcoming year during the House of Delegates session held in conjunction with NCPA’s 115th Annual Convention and Trade Exposition.
Mark Riley, was named NCPA president. Riley is currently EVP of the Arkansas Pharmacists Association and owns East End Pharmacy in Little Rock, Ark. He is also one of the country’s foremost experts on the pharmacy benefit manager industry, having served as a PBM executive, and has appeared on Capitol Hill numerous times as a subject matter expert on the complicated topic, NCPA noted.
“We congratulate Mark on his appointment as president of NCPA,” stated NCPA CEO Douglas Hoey. “Mark is a distinguished leader known and respected by many independent community pharmacists. We thank him for all of his previous service to NCPA and for taking on this position. NCPA members are fortunate to have a world-class assembly of community pharmacy owners and pharmacists serving as officers to lead their trade association.”
NCPA members voted to approve the following resolutions for NCPA:
- To encourage its members to engage self-insured employers in their communities to “make them aware that there are plan designs that are flexible, transparent, maximize cost savings and health outcomes, and are both pro-patient and pro-small business,” as opposed to arrangements that restrict patient choice, such as mandatory mail order;
- To work with stakeholders across the independent community pharmacy industry “to promote existing resources and facilitate greater use of them to assist in the transfer of independent pharmacies from one independent owner to another;”
- To address the inequity between large corporations that can pay effective tax rates that are far below those of small business community pharmacies, many of which are incorporated as S Corporations, NCPA should “advocate for a lowering of the effective tax rate for S Corporations or pass through entities as part of any congressional efforts to reform the nation’s tax code;"
- To respond to the rise of specialty pharmaceuticals and specialty pharmacies by supporting a standard definition of “specialty” that is developed by the pharmacy profession and that is “not based primarily on pricing or other arbitrary standards that limit patient access.” The lack of a standard definition today may allow pharmacy benefit managers to arbitrarily categorize such drugs in order to maximize PBM profitability while limiting patient choice;
- To support the right of community pharmacists to compound medications without restrictive regulations and under the continued oversight of individual state boards of pharmacy;
- To promote policies and legislation that addresses alleged misuse by PBMs of maximum allowable cost drug reimbursement caps. Such policies and legislation should provide pharmacists and plan sponsors clarity into how MAC pricing is determined; establish a timely appeals process to resolve disputes; implement standardization as to how MACs are applied to certain medications; and require PBM disclosure to clients of the existence of multiple MAC lists as well as which, if any, MAC pricing is used in their mail order pharmacies; and
- To examine possible solutions, including potential state and federal legislation, to ensure that third-party payers update their reimbursement on a real-time basis in order to pay pharmacies rates that reflect their cost of acquiring prescription drugs. In light of technology advances over the past decade, it is “outrageous and unacceptable that in the face of radically rising product prices, especially for generic drugs, payers are delaying drug price updates resulting in delayed drug reimbursement adjustments to pharmacies for weeks and even months.”
“These resolutions speak to many of the challenges that independent community pharmacists face today as they try to continue serving patients,” Hoey said.
In addition, Jeff Harrell joins NCPA’s leadership as fourth VP. He is co-owner of six pharmacies in Washington state, most of them located in the state’s southwestern Peninsula region, and all a part of Penninsula Pharmacies. Harrell managed an independent pharmacy in Seattle before returning to his native Long Beach, Wash., to become co-owner of Penninsula Pharmacies. He is a leading authority on technology innovations in pharmacy practice and a graduate of Washington State University, where he earned a Doctor of Pharmacy degree, NCPA stated.
Kristen Riddle was named fifth VP. She is president, director of clinical services for U.S. Compounding Pharmacy, a PCAB-accredited, compounding-only pharmacy located in Conway, Ark. She is also partner/owner in Adherence Model Pharmacy. Riddle is passionate about women’s health and is co-creator of the Rx Skin Therapy line of cosmeceutical skin care products available without a prescription. She earned a Doctor of Pharmacy degree from the University of Arkansas for Medical Sciences, College of Pharmacy, according to NCPA.